IQVIA Holdings Inc. $IQV Shares Purchased by MassMutual Private Wealth & Trust FSB

MassMutual Private Wealth & Trust FSB boosted its position in IQVIA Holdings Inc. (NYSE:IQV) by 16.6% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,100 shares of the medical research company’s stock after purchasing an additional 157 shares during the period. MassMutual Private Wealth & Trust FSB’s holdings in IQVIA were worth $173,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Sowell Financial Services LLC acquired a new stake in shares of IQVIA during the 1st quarter valued at $305,000. Mather Group LLC. boosted its position in shares of IQVIA by 83.5% in the first quarter. Mather Group LLC. now owns 769 shares of the medical research company’s stock worth $136,000 after buying an additional 350 shares during the period. Private Advisor Group LLC boosted its position in shares of IQVIA by 11.6% in the first quarter. Private Advisor Group LLC now owns 5,435 shares of the medical research company’s stock worth $958,000 after buying an additional 566 shares during the period. Park Avenue Securities LLC boosted its position in shares of IQVIA by 40.4% in the first quarter. Park Avenue Securities LLC now owns 5,425 shares of the medical research company’s stock worth $956,000 after buying an additional 1,562 shares during the period. Finally, Wealth Enhancement Advisory Services LLC boosted its position in shares of IQVIA by 34.5% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 13,259 shares of the medical research company’s stock worth $2,338,000 after buying an additional 3,398 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Stock Up 1.9%

IQV stock opened at $190.17 on Friday. IQVIA Holdings Inc. has a twelve month low of $134.65 and a twelve month high of $248.03. The company has a market cap of $32.33 billion, a PE ratio of 27.52, a price-to-earnings-growth ratio of 2.05 and a beta of 1.32. The business’s 50-day simple moving average is $184.30 and its 200 day simple moving average is $167.42. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.45.

IQVIA (NYSE:IQV) last released its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, topping analysts’ consensus estimates of $2.77 by $0.04. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The business had revenue of $4.02 billion for the quarter, compared to the consensus estimate of $3.96 billion. During the same period last year, the business earned $2.64 earnings per share. The firm’s revenue for the quarter was up 5.3% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. On average, research analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Eric Sherbet sold 5,800 shares of IQVIA stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the completion of the transaction, the insider owned 27,178 shares in the company, valued at approximately $5,165,178.90. The trade was a 17.59% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Keriann Cherofsky sold 549 shares of the company’s stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the transaction, the insider directly owned 2,910 shares in the company, valued at approximately $557,352.30. This represents a 15.87% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several analysts have recently commented on the company. Citigroup reaffirmed a “neutral” rating on shares of IQVIA in a research report on Thursday, May 22nd. William Blair reaffirmed an “outperform” rating on shares of IQVIA in a research report on Wednesday, July 23rd. Robert W. Baird raised their target price on IQVIA from $159.00 to $196.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 23rd. Redburn Partners set a $214.00 target price on IQVIA in a research report on Wednesday, September 3rd. Finally, UBS Group increased their price objective on IQVIA from $185.00 to $225.00 and gave the stock a “buy” rating in a report on Wednesday, July 23rd. Eighteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, IQVIA has an average rating of “Moderate Buy” and a consensus target price of $229.64.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.